NextBioMedical Co

NextBioMedical Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 252.11 %. In the previous year, CapEx to Operating Cash Flow Ratio was -36.60 % — a change of -788.85% (higher).

CapEx/OCF

252.11 %

YoY

-788.85%

Last updated:

CapEx to Operating Cash Flow Ratio of NextBioMedical Co is 2025 252.11 % . CapEx to Operating Cash Flow Ratio of NextBioMedical Co was 2024 -36.60 % . It decreases by -788.85% higher compared to the previous year.

The NextBioMedical Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2021
-14.35 KRW
Jan 1, 2022
-2.38 KRW
Jan 1, 2023
-1.55 KRW
Jan 1, 2024
-36.60 KRW
Jan 1, 2025
252.11 KRW
The NextBioMedical Co CapEx/OCF history
YEARCapEx/OCFYoY
252.11 %-788.85%
-36.60 %+2,259.05%
-1.55 %-34.72%
-2.38 %-83.44%
-14.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

CapEx to Operating Cash Flow Ratio of NextBioMedical Co is 252.11 % in 2025.

CapEx to Operating Cash Flow Ratio of NextBioMedical Co changed from -36.60 % to 252.11 %, representing a -788.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's NextBioMedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NextBioMedical Co

All Key Metrics — NextBioMedical Co